Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk RNAseq of the kidneys from diabetic mice with MAT2A inhibitor

ABSTRACT: These analysis detected the Loci of genes regulated in a SAM-dependent manner.

ORGANISM(S): Mus musculus

PROVIDER: GSE268592 | GEO | 2025/07/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CUT&RUN of the kidneys from diabetic mice with MAT2A inhibitor II

Project description:H3K27me3 was enhanced in the gene loci related to the inflammatory pathway.

2025-07-09 | GSE268596 | GEO

CUT&RUN of the kidneys from diabetic mice with MAT2A inhibitor I

Project description:H3K27me3 was enhanced in the gene loci related to the inflammatory pathway.

2025-07-09 | GSE268595 | GEO

Bulk RNAseq of the kidneys from diabetic mice with MAT2A inhibitor

Project description:Bulk RNAseq of the kidneys from diabetic mice with MAT2A inhibitor

| PRJNA1117869 | ENA

Diabetic mice with MAT2A inhibitor

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-07-09 | GSE268597 | GEO

Diabetic mice with MAT2A inhibitor

Project description:Diabetic mice with MAT2A inhibitor

| PRJNA1117870 | ENA

CUT&RUN of the kidneys from diabetic mice with MAT2A inhibitor I

Project description:CUT&RUN of the kidneys from diabetic mice with MAT2A inhibitor I

| PRJNA1117866 | ENA

CUT&RUN of the kidneys from diabetic mice with MAT2A inhibitor II

Project description:CUT&RUN of the kidneys from diabetic mice with MAT2A inhibitor II

| PRJNA1117875 | ENA

MAT2A as key regulator and therapeutic target in MLL leukemogenesis

Project description:Epigenetic dysregulation plays a pivotal role in MLL pathogenesis, therefore serving as suitable therapeutic point of attack. SAM is the universal methyl donor in human cells and is synthesized by MAT2A. MAT2A is already known to be deregulated in different cancer types. Here, we used our human CRISPR/Cas9-MLLr leukemia model, faithfully mimicking MLL patients’ pathology with indefinite growth potential in in vitro culture, to evaluate the unknown role of MAT2A as therapeutic target. Comparable to publicly available patient data, we detected MAT2A to be significantly overexpressed in our CRISPR/Cas9-MLLr model compared to healthy controls. By using non-MLLr and MLLr cell lines and our model, we detected an MLLr specific enhanced response to PF-9366, a new MAT2A inhibitor, by alteration of proliferation, viability, differentiation, apoptosis and cell cycling. Moreover, the combinational treatment of PF-9366 with chemotherapy or targeted therapies against the SAM-dependent methyltransferases DOT1L and PRMT5, revealed even more pronounced effects. In summary, we uncovered MAT2A as a key regulator in MLL leukemogenesis and its inhibition led to significant anti-leukemic effects. Therefore, our study paves the avenue for clinical application of PF-9366 to improve the treatment of poor prognosis MLLr leukemia.

2020-06-22 | GSE141839 | GEO

Antarctic Clam Laternula elliptica bulk RNAseq developmental stages

Project description: Not available

| S-BSST926 | biostudies-other

NUDT21 regulates intron detention of the SAM synthetase MAT2A RNA

Project description:NUDT21 encodes the CFIm25 protein, a component of the CFIm complex that regulates alternative polyadenylation (APA). Our data suggest that the CFIm complex also induces splicing of a detained intron in the the S-adenosylmethionine (SAM) synthetase MAT2A to control intracellular levels of SAM. To genetically separate these functions, we used poly(A) Click-seq (PAC-seq) to determine the changes in poly(A) site selection in two cell lines. The parental cell line is the colorectal cell line HCT116 and a derivative line that has the detained intron of MAT2A deleted in both alleles of MAT2A (116-DDI). We found few differences in alternative polyadenylation after CFIm25 depletion were similar supporting teh conclusion that CFIm's role in APA is mechanistically distinct from its role in regulation of MATA splicing.

2021-05-04 | GSE158591 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data